Industry: Healthcare | Publish Date: 03-Sep-2025 | No of Pages: 90 | No. of Tables: 96 | No. of Figures: 61 | Format: PDF | Report Code : HC1130
The Vietnam Professional Acne Medication Market was valued at USD 16.14 million in 2023 and is predicted to reach USD 32.98 million by 2030, with a CAGR of 10.7% from 2024 to 2030. The market includes specialized skincare formulations produced and recommended by dermatologists and skincare specialists to address acne-related issues. Its key goals include offering focused and efficient remedies for various forms of acne, such as inflammatory and non-inflammatory lesions, as well as reducing acne scarring.
The benefits of professional acne medication stems from the powerful and personalized formulations, which frequently include clinically validated components that may be more potent than over-the-counter alternatives. These drugs, which are widely used in dermatological offices, cater to those who have severe or persistent acne problems, providing a better level of effectiveness and control. As the demand for sophisticated skincare treatments grows, the professional acne medication market continues to play an important role in achieving cleaner, healthier skin through individualized and medically directed procedures.
The expanding cosmetic industry in Vietnam is significantly influencing the demand for professional acne medication. As more consumers invest in beauty and skincare products, there is a parallel rise in the need for effective acne treatments to maintain clear and healthy skin. The growing use of cosmetics has led to increased consumer awareness about skin health, encouraging individuals to seek professional dermatological solutions. This trend is fueling the adoption of advanced acne medications across the country.
Supportive government efforts aimed at enhancing skincare awareness and dermatological research are contributing to the growth of Vietnam's professional acne medication market. Initiatives promoting innovation in personalized skincare solutions and the integration of technology in dermatology are improving access to effective acne treatments. These strategic efforts are fostering a more informed consumer base and encouraging the use of professional products for acne management throughout the country.
In Vietnam, the professional acne medication market faces a notable challenge due to the high cost associated with prescription-based treatments and advanced dermatological products. These medications, often recommended by healthcare professionals, remain financially out of reach for a significant portion of the population. This cost barrier limits consumer access to professional-grade skincare solutions, prompting many individuals to turn to more affordable over-the-counter products or traditional remedies. Consequently, the preference for less expensive alternatives reduces the demand for professional treatment options, thereby restraining the market’s growth across the country.
The integration of AI-powered skin diagnosis into acne treatment presents a significant growth opportunity for the professional acne medication market in Vietnam. Advanced skincare devices and mobile applications equipped with artificial intelligence are increasingly being used to assess skin conditions in real time, accurately identifying acne severity and recommending personalized treatment regimens. This technological innovation aligns with the rising consumer demand in Vietnam for tailored and effective skincare solutions. In March 2025, SmartSKN Labs introduced K-OWN, an AI-driven platform within the Vietnamese market that enables users to create personalized skincare formulations based on individual skin profiles. The adoption of such platforms is expected to improve diagnostic precision, enhance treatment outcomes, and strengthen consumer confidence in professional acne care, thereby driving market expansion in the country.
The Vietnam professional acne medication industry includes several market players such as Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Bio Atoms, Beiersdorf AG, Galderma, Vinapharco, CPC1 Hà Nội, Dermafirm, MD CARE CO., LTD., and others.
Inflammatory Acne
Non-inflammatory Acne
By Formulation
Topical Medications
Combination Treatments
Laser And Light-Based Treatments
Oral Medications
By Acne Severity
Mild Acne
Moderate Acne
Severe Acne
Post-Inflammatory Hyperpigmentation (Pih)
By Skin Type
Normal/Combination Skin
Dry Skin
Oily Skin
Sensitive Skin
By Age Group
Teenagers and Young Adults (13-30 Years)
Adults (31 years and above)
By Therapeutic Class
Retinoids
Antibiotics
Salicylic Acid
Benzoyl Peroxide
Others
By Application
Facial Acne Treatment
Body Acne Treatment
Scalp Acne Treatment
By Distribution Channel
Dermatologist & Aesthetician
Pharmacies & Drug Store
E-Commerce
Others
Key Players
Bayer AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Bio Atoms
Beiersdorf AG
Galderma
Vinapharco
CPC1 Hà Nội
Dermafirm
MD CARE CO., LTD.
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Market Size in 2023 |
USD 16.14 Million |
Revenue Forecast in 2030 |
USD 32.98 Million |
Growth Rate |
CAGR of 10.7% from 2024 to 2030 |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Million (USD) |
Growth Factors |
|
Key Market Players |
10 |
Market Share |
Available for 10 companies |
Customization Scope |
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and Purchase Options |
Avail customized purchase options to meet your exact research needs. |